VAERS Explorer
Back to explore

Report #2856628

Received Sep 3, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex
Unknown
Age
Age unknown
State
LA
Recovered
Unknown
Vaccinated
Aug 11, 2025
Onset
Aug 11, 2025
Days to onset
0
Hospital days
—

Vaccines (4)

TypeNameManufacturerDoseLotRoute / Site
HEPHEP B (RECOMBIVAX HB)MERCK & CO. INC.4Y007989—
HEPHEP B (RECOMBIVAX HB)MERCK & CO. INC.1——
HEPHEP B (RECOMBIVAX HB)MERCK & CO. INC.2——
HEPHEP B (RECOMBIVAX HB)MERCK & CO. INC.3——

Symptoms (3)

Extra dose administeredInappropriate schedule of product administrationNo adverse event

Symptom narrative

No reported side effects.; Caller also stated the 3rd dose was administered late; 2 year old child was administered an additional dose of RECOMBIVAX HB; This spontaneous report was received from a nurse and refers to a 2-year-old patient of unknown gender. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On an unknown date, the patient started therapy with Hepatitis B Vaccine (Recombinant) (RECOMBIVAX HB), Suspension for injection, dose number 1, (lot # and expiration date, route of administration and anatomical location were not reported) for prophylaxis. On an unknown date, the patient was vaccinated with Hepatitis B Vaccine (Recombinant) (RECOMBIVAX HB), Suspension for injection, dose number 2, (lot # and expiration date, route of administration and anatomical location were not reported) for prophylaxis. On an unknown date, the patient was vaccinated with Hepatitis B Vaccine (Recombinant) (RECOMBIVAX HB), Suspension for injection, dose number 3, (lot # and expiration date, route of administration and anatomical location were not reported) for prophylaxis and that dose was administered late (Inappropriate schedule of vaccine administered). On 11-AUG-2025, the patient was vaccinated with additional dose of Hepatitis B Vaccine (Recombinant) Suspension for injection (RECOMBIVAX HB) (lot #Y007989 was valid for formulation pre-filled syringe, expiration date: 06-DEC-2026, dose number 4, route of administration and anatomical location were not reported) for prophylaxis (Extra dose administered). No additional information to report. No reported side effects (No adverse event). No product quality complaint (PQC).